On March 26, 2026, Pinnacle Medicines, a biotechnology company pioneering the development of oral peptide therapeutics using proprietary AI and physics-based platforms, announced the closing of an oversubscribed $89 million Series B financing. The round was co-led by LAV and Foresite Capital, with participation from Quan Capital, Hankang Capital, RA Capital Management, Logos Capital, and existing investors including OrbiMed. Wilson Sonsini Goodrich & Rosati advised Pinnacle on corporate and IP matters related to the transaction.

Proceeds from the financing will support the advancement of Pinnacle's lead programs through clinical proof of concept, with an initial focus on immunology and cardiometabolic diseases, while further expanding the company's proprietary peptide discovery platform and research and development capabilities.

The Wilson Sonsini team that advised Pinnacle on corporate and IP matters related to the transaction includes Karen Deschaine, Michael Hostetler, Ying Chen, Johnson Truong, and Céline Bonnefous.

For more information, please see Pinnacle’s news release.